AstraZeneca Focus On China, Emerging Markets, Not Acquisitions
This article was originally published in PharmAsia News
U.K.-based AstraZeneca plans to take a path to growth that is different from most of its global competitors; shun acquisitions and concentrate on China. CEO David Brennan says his company does not need a merger or a major acquisition to fare well in the pharmaceutical marketplace, unlike other companies about to participate in another merger mania. Mergers often are considered the best response to periods when drug pipelines are diminished by products losing patent protection. Brennan believes a better response is a focus on reducing costs at home and looking to emerging markets for sales and to instigate innovation. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.